Clene Inc. Debt Securities, Available-for-sale, Allowance for Credit Loss
Clene Inc. (CLNN) had Debt Securities, Available-for-sale, Allowance for Credit Loss of $0 as of 2025-03-31, per its 10-Q filed 2025-05-07.
Financial Statements › Notes
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss · last filed 2025-05-07
- 2025-03-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2024-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2024-09-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2024-06-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss |
|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 |
| 2024-12-31 | $0.00 10-Q · filed 2025-05-07 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-24 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |